UNCY Unicycive Therapeutics Inc
1,671
$1.09
$0.04
(3.54%)
| Watchers | 1,671 |
| 52-Wk Low | $0.47 |
| 52-Wk High | $1.82 |
| Market Cap | $42.5M |
| Volume | 47,010.00 |
| 52-Wk High | $1.82 |
| 52-Wk Low | $0.47 |
Unicycive Therapeutics initiated with bullish view at Piper Sandler, here's whyThe Fly • about 1 month ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
HC Wainwright reiterated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY - Free Report) in a report published on Monday, Benzinga reports. The firm currently has a $4.50 price...
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY Research Report), with a price t...
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 56,700 shares, a...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
UNCY stock results show that Unicycive Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury UNI-494 Phase 1 Single Ascending Dose...
LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics (NASDAQ:UNCY Get Free Report)s stock had its buy rating reissued by analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga...
Led by new investors Octagon Capital and Great Point Partners, LLC, with participation from new and existing investors including Logos Capital, Nantahala Capital, SilverArc Capital, Velan Capital...